TY  - BOOK
AU  - Shorr, Andrew F
TI  - Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials
SN  - 0732-8893
PY  - 2013///
KW  - *Anti-Bacterial Agents/tu [Therapeutic Use]
KW  - *Cephalosporins/tu [Therapeutic Use]
KW  - *Community-Acquired Infections/dt [Drug Therapy]
KW  - *Pneumonia, Pneumococcal/dt [Drug Therapy]
KW  - Aged
KW  - Aged, 80 and over
KW  - Bacteremia/dt [Drug Therapy]
KW  - Bacteremia/mi [Microbiology]
KW  - Ceftriaxone/tu [Therapeutic Use]
KW  - Community-Acquired Infections/mi [Microbiology]
KW  - Female
KW  - Humans
KW  - Logistic Models
KW  - Male
KW  - Microbial Sensitivity Tests
KW  - Middle Aged
KW  - Odds Ratio
KW  - Pneumonia, Pneumococcal/mi [Microbiology]
KW  - Retrospective Studies
KW  - Treatment Outcome
KW  - MedStar Washington Hospital Center
KW  - Medicine/Pulmonary-Critical Care
KW  - Clinical Trial, Phase III
KW  - Journal Article
KW  - Multicenter Study
KW  - Randomized Controlled Trial
KW  - Research Support, Non-U.S. Gov't
N2  - Ceftaroline fosamil resulted in higher cure rates than ceftriaxone in patients with community-acquired bacterial pneumonia in 2 randomized trials (FOCUS 1 and FOCUS 2). The present analysis examines the subgroup of patients with Streptococcus pneumoniae infection to determine whether the apparent difference in cure rates persists after adjusting for potential covariates. We retrospectively pooled subjects with S. pneumoniae isolated at baseline in the original studies and employed logistic regression to evaluate the independent relationship between clinical cure and treatment with ceftaroline. Covariates evaluated included demographics, severity of illness, bacteremia, and pathogen characteristics. The final cohort included 139 subjects (69 ceftaroline, 70 ceftriaxone). Unadjusted cure rates were 85.5% and 68.6% (P = 0.009) in the ceftaroline and ceftriaxone groups, respectively. After logistic regression, ceftaroline remained associated with higher cure rates. Our findings indicate that ceftaroline may result in improved outcomes of S. pneumoniae pneumonia. Formal clinical trials are warranted to confirm this hypothesis. Copyright  2013 Elsevier Inc. All rights reserved
UR  - http://dx.doi.org/10.1016/j.diagmicrobio.2012.12.002
ER  -